Trial Profile
An Open-Label, 2-Part, Multicenter, Post-marketing Study to Evaluate the Effect of Moderately or Severely Active Ulcerative Colitis or Crohn's Disease on Cytochrome P-450 Enzyme Substrates Compared to Healthy Subjects and the Effect of Vedolizumab Treatment on Cytochrome P-450 Enzyme Substrates in Subjects With Ulcerative Colitis or Crohn's Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary) ; Caffeine; Dextromethorphan; Losartan; Midazolam; Omeprazole
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Takeda
- 23 Oct 2020 Status changed from suspended to withdrawn prior to enrolment.
- 19 Dec 2019 Status changed from recruiting to suspended.
- 19 Dec 2019 Planned End Date changed from 29 Jul 2019 to 1 Aug 2020.